Implementation of the Guidelines for Oncolytic Viruses in China

Meng Qinghe; Wang Shuling; Yang Mo

Asian Journal of Social Pharmacy ›› 2024, Vol. 19 ›› Issue (4) :344 -350.

research-article

Implementation of the Guidelines for Oncolytic Viruses in China

Author information +

History +

Abstract

Objective To study related guidelines such as “Guidelines for Clinical Trial Design of Oncolytic Viruses” “Technical Guidelines for Non-clinical Research and Evaluation of Gene Therapy Products” and “Technical Guidelines for Pharmacological Research and Evaluation of Oncolytic Viruses (OVs) Products” issued by the Center for Drug Evaluation (CDE) on OV and offer some suggestions for further improvement of the policies and regulations. Methods Literature comparison and questionnaire survey were used in this paper to investigate the difficulties encountered in the practical work of domestic companies that have conducted clinical trials, thus drawing some lessons to help the subsequent implementation of the guidelines. Results and Conclusion According to the characteristics of specific varieties and the published laws, regulations and guidelines, companies can adopt more suitable and scientific strategies to accelerate the development of anti-cancer drugs. In the future, as more clinical studies and product development for various cancers expand, regulatory requirements are expected to become more specialized and complex. Learning from the regulatory experience of developed countries and regions, we can improve the regulatory system by adapting it to national conditions and development status of China. Additionally, some ideas and useful inspirations can be provided after reviewing the content of the relevant guidelines and the obstacles in the practice of corporate R&D process can be addressed. These efforts will facilitate the speed of R&D and allow enterprises to work more smoothly and efficiently.

Keywords

oncolytic virus / guideline / questionnaire / regulatory system

Cite this article

Download citation ▾

Meng Qinghe, Wang Shuling, Yang Mo. Implementation of the Guidelines for Oncolytic Viruses in China. Asian Journal of Social Pharmacy, 2024, 19(4): 344-350 DOI:

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Zou Y, Luo Y, Zhang J, et al. Bibliometric analysis of oncolytic virus research, 2000 to 2018[J]. Medicine (Baltimore), 2019, 98 (35): e16817.

[2]	Mozaffari Nejad AS, Noor T, Munim ZH, et al. A bibliometric review of oncolytic virus research as a novel approach for cancer therapy[J]. Virology Journal, 2021, 18 (1): 98-112.

[3]	Du S, Jiang K, Ding C, et al. Oncolytic newcastle disease virus: A new opportunity in the era of tumor immunotherapy[J]. Scientia Sinica (Vitae), 2021, 51: 1623-1636. (in Chinese)

[4]	Macedo N, Miller DM, Haq R, et al. Clinical landscape of oncolytic virus research in 2020[J]. Journal for Immuno Therapy of Cancer, 2020, 8 (2): e001486.

[5]	Zeng Xin, Wang Chen, Xi Rui, et al. Research status and clinical progress of oncolytic virus[J]. Progress in Pharmaceutical Sciences, 2021, 45 (10): 735-742.

[6]	Yang Hao, Zhang Shaogeng, Yang Penghui. Immunologic mechanisms and clinical research progress of oncolytic viruses[J]. Progress in Biochemistry and Biophysics, 2022, 49 (8): 1398-1405.

[7]	Center for Drug Evaluation, NMPA. Guidelines for Clinical Trial Design of Oncolytic Virus (Trial)[EB/OL]. (2021-02-09)[2021-10-15]. https://www.cde.org.cn/main/news/viewInfoCommon/a58d1fe54b9cd01161bc143a8ba1a600.

[8]	Center for Drug Evaluation, NMPA. Technical Guidelines for Pharmacological Research and Evaluation of Oncolytic Virus Products (Draft for Comments)[EB/OL]. (2020-09-14)[2021-10-15].

[9]	Center for Drug Evaluation, NMPA. Technical Guidelines for Non-clinical Research and Evaluation of Gene Therapy Products (Draft for Comments)[EB/OL]. (2021-02-09)[2021-10-15]. https://www.cde.org.cn/main/news/viewInfoCommon/9398dd75b31c67843609bc669b5798de.

[10]	Food and Drug Administration. Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products[S]. 2015.

[11]	ICH Considerations. Oncolytic Viruses[S]. 2009.

[12]	European Medicines Agency. Guideline on the Quality,Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products[S]. 2015.

[13]	Li Yu. International experience and enlightenment of cell gene therapy regulatory[D]. Southeastern University, 2020.

[14]	Liu Xiaodan, Wang Xinyi, Cao Meng. Research progress on gene therapy products and analysis of domestic and foreign regulatory systems[J]. Chinese Journal of Pharmaceuticals, 2021, 52 (8): 1097-1105.

[15]	Cui Jing, Xu Longchang, Li Qian. Challenge analysis of oncolytic viruses in manufacturing process and quality control in China[J]. Chinese Pharmaceutical Journal, 2021, 56 (24): 2029-2034.

[16]	Wei Wei, Lu Jiaqi, Bai Yu, et al. Quality study and assessment of oncolytic virus products[J]. Chinese Journal of Immunology, 2019, 35 (13): 1656-1661.

[17]

EMA. Guideline on Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products[EB/OL]. (2018-03-22)[2022-04-01]. https://www.ema.europa.eu/en/documents/scientific-guideline/guide-line-scientific-requirements-environmental-risk-assessment-gene-therapy-medicinal-products_en.pdf.

[18]	Zhang Min, Gong Xinjiang, Shao Xue, et al. Introduction to the ICH considerations on nonclinical studies of oncolytic virus products in conjugation with the practice of talimogene laherparepvec[J]. Chinese Journal of New Drugs, 2019, 28 (16): 1982-1986.

[19]	Center for Drug Evaluation, NMPA. Technical Guidelines for Non-clinical Research and Evaluation of Gene Modified Cell Therapy Products (Draft for Comments)[EB/OL]. (2021-02-23)[2021-10-15]. https://www.cde.org.cn/main/news/viewInfoCommon/d26ae045f21823331a435bc48469fd3b.

[20]	Wang Xin, Miao Yufa, Huo Yan, et al. Pre-clinical evaluation of oncolytic virus drugs[J]. China Pharmacovigilance, 2021, 18 (6): 597-600.

[21]	Reale A, Calistri A, Palù G. A clinical trial investigating biodistribution and shedding of an oncolytic virus[J]. eBioMedicine, 2019, 47: 4-5.

[22]	Ye Xuan, Zhang Min, Yan Liping, et al. Specific considerations in the implementation of S9 in ICH guideline in China[J]. Chinese Journal of New Drugs, 2020, 29 (15): 1717-1722.

[23]	Zhang Sucai, Gong Tiantian, Zhang Dongxia, et al. Non-clinical assessment of the safety of oncolytic virus[J]. Central South Pharmacy, 2019, 17 (9): 1391-1395.

[24]	Xu Qing, Lu Shun, Zhu Huiyan. Shanghai expert consensus on clinical application of oncolytic virus for malignant tumors[J]. China Oncology, 2021, 31 (3): 231-240.

[25]	Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy[J]. Human Vaccines & Immunotherapeutics, 2020, 16 (10): 2389-2402.

[26]	Liu Xiao, Huang Yunhong, Gao Chenyan. Progress in clinical study of intra-cavity administration of oncolytic virus[J]. Chinese Journal of New Drugs 2021, 30 (19): 1814-1818.

[27]	Ning Xiaoping, Yu Gan jun. Progress of oncolytic virus in clinic[J]. Chinese Journal of Cancer Biotherapy, 2020, 27 (6): 705-710.

[28]	Li Xue, Huang Lili, Xie Haiyan. Status and prospects of oncolytic virotherapy[J]. Chinese Journal of Cancer Biotherapy, 2020, 27 (6): 705-710.

[29]	Chen Jianhua, Sun Ying, Duan Yourong. Progress in systemic administration of adenovirus vector for cancer gene[J]. Tumor, 2017, 37 (12): 1339-1343.

[30]	Wang Lei, Huo Bin, Huo Xiaodong. Progress in clinical application of oncolytic virus in cancer treatment[J]. Chinese Journal of Clinical Oncology, 2021, 48 (11): 581-586.

[31]	Bian Jing, Zhu Meiling, Li Xiayi, et al. Progress of oncolytic virus in treatment of gastric cancer[J]. Tumor, 2020, 40 (3): 223-232.

[32]	Oh CM, Chon H, Kim C. Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors[J]. International Journal of Molecular Sciences, 2020, 21 (20): 7743.